EFFECT OF THE Pro12Ala POLYMORPHISM OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ2 GENE ON LIPID PROFILE AND ADIPOKINES LEVELS IN OBESE SUBJECTS
Becer E1,2,*, Çırakoğlu A3
*Corresponding Author: Eda Becer, Ph.D., M.Sc., Department of Biochemistry, Faculty of Pharmacy, Near East University, Nicosia, Mersin 10, Turkey. Tel: +90-392-680-2000, Ext: 128. Fax:+90-392-680-2038. E-mail: edabecer@yahoo.com
page: 71
|
|
REFERENCES
1. Stump M, Mukohda M, Hu C, Sigmund CD. PPARγ regulation in hypertension and metabolic syndrome. Curr Hypertens Rep. 2015; 17(12): 1-9. 2. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological
outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 2006; 45(2): 120-159. 3. Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, et al. The common PPAR-γ2 Pro12 Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet. 2004; 12(12): 10501054. 4. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, et al. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell. 1999; 4(4): 597-609. 5. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz Md, Moller DE, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors γ1 and γ2. Biochem Biophys Res Commun. 1996; 224(2): 431-437. 6. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: Identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun. 1997; 241(2): 270-274. 7. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998; 20(3): 284-287. 8. Yao YS, Li J, Jin YL, Chen Y, He LP. Association between PPAR-γ2 Pro12Ala polymorphism and obesity: A meta-analysis. Mol Biol Rep. 2015; 42(6): 10291038. 9. Tönjes A, Stumvoll M. The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk. Curr Opin Clin Nutr Metab Care. 2007; 10(4): 410-414. 10. Moon MK, Cho YM, Jung HS, Park YJ, Yoon KH, Sung YA, et al. Genetic polymorphisms in peroxisome proliferator-activated receptor γ are associated with type 2 diabetes mellitus and obesity in the Korean population. Diabet Med. 2005; 22(9): 1161-1166. 11. Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clément K, Charles MA, et al. Implication of the Pro12Ala polymorphism of the PPAR-γ2 gene in type 2 diabetes and obesity in the French population. BMC Med Genet. 2005; 6(11): 1-8. 12. Ben Ali S, Ben Yahia F, Sediri Y, Kallel A, Ftouhi B, Feki M, et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem. 2009; 42(1617): 1642-1647. 13. Takata N, Awata T, Inukai K, Watanabe M, Ohkubo T, Kurihara S, et al. Pro12Ala substitution in peroxisome proliferator-activated receptor γ2 is associated with low adiponectin concentrations in young Japanese men. Metabolism. 2004; 53(12): 1548-1551. 14. World Health Organization. Physical status: The use and interpretation anthropometry: Report of a WHO Expert Committee, WHO Technical Report Series, no. 854. Geneva, Switzerland: WHO. 1995; 321-344. 15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985; 28(7): 412-419. 16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3): 1215. 17. Tellechea ML, Aranguren F, Perez MS, Cerrone GE, Frechtel GD, Taverna MJ. Pro12Ala polymorphism of the peroxisome proliferator activated receptor-γ gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men: Interaction with smoking status. Circ J. 2009; 73(11): 2118-2124. 18. Beamer BA, Yen CJ, Andersen RE, Muller, Elahi D, Cheskin LJ, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes. 1998; 47(11): 1806-1808. 19. Masud S, Ye S; SAS Group. Effect of the peroxisome proliferator activated receptor-γ gene Pro12Ala variant on body mass index: A meta-analysis. J Med Genet. 2003; 40(10): 773-780. 20. Gonzalez Sanchez JL, Serrano Rios M, Fernandez Perez C, Laakso M, Martinez Larrad MT. Effect of the Pro12Ala polymorphism of the peroxisome proliferator activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol. 2002; 147(4): 495-501. 21. Moffett SP, Feingold E, Barmada MM, Damcott CM, Marshall JA, Hamman RF, et al. The C161→T polymorphism in peroxisome proliferator-activated receptor γ, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women:
Evidence for another functional variant in peroxisome proliferator-activated receptor γ. Metabolism. 2005; 54(11): 1552-1556. 22. Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL, Beilby JP. A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-γ2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol. 2001; 144(3): 277-282. 23. Paracchini V, Pedotti P, Taioli E. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol. 2005; 162(2): 101-114. 24. Schneider J, Kreuzer J, Hamann A, Nawroth PP, Dugi KA. The proline 12 alanine substitution in the peroxisome proliferator – Activated receptor-γ2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes. 2002; 51(13): 867-870. 25. Hollenberg AN, Susulic VS, Madura JP, Zhang B, Moller DE, Tontonoz P, et al. Functional antagonism between CCAAT/enhancer binding protein-α and peroxisome proliferator-activated receptor-γ on the leptin promoter. J Biol Chem. 1997; 272(8): 5283-5290. 26. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest. 2004; 113(6): 846855. 27. Simón I, Vendrell J, Gutiérrez C, Fernández-Real JM, Vendrell I, Gallart L, et al. Pro12Ala substitution in the peroxisome proliferator-activated receptor-γ is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res. 2002; 58(3): 143-149. 28. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50(9): 2094-2099. 29. Moseti D, Regassa A, Kim WK. Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules. Int J Mol Sci. 2016; 17(1): 1-24. 30. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: The atherosclerosis risk in communities study. Diabetes. 2004; 53(9): 2373-2478. 31. Mousavinasab F, Tähtinen T, Jokelainen J, Koskela P, Vanhala M, Oikarinen J, et al. Common poly-mor phisms (single-nucleotide polymorphisms SNP+45 and SNP+276) of the adiponectin gene regulate serum adiponectin concentrations and blood pressure in young Finnish men. Mol Genet Metab. 2005; 87(2): 147-151. 32. Bhatt SP, Misra A, Sharma M, Luthra K, Guleria R, Pandey RM. Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther. 2012; 14(9): 828-834. 33. Takata N, Awata T, Inukai K, Watanabe M, Ohkubo T, Kurihara S, et al. Pro12Ala substitution in peroxisome proliferator-activated receptor γ2 is associated with low adiponectin concentrations in young Japanese men. Metabolism. 2004; 53(12): 1548-1551. 34. Yamamoto Y, Hirose H, Miyashita K, Nishikai K, Saito I, Taniyama M, et al. PPAR(γ)2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism. 2002; 51(11): 1407-1409.
35. Vázquez-Del Mercado M, Guzmán-Ornelas MO, Corona Meraz FI, Ríos-Ibarra CP, Reyes-Serratos EA, Ruíz-Quezada SL, et al. The 482Ser of PPARGC1A and 12Pro of PPARG2 alleles are associated with reduction of metabolic risk factors even obesity in a Mexican-Mestizo population. Biomed Res Int. 2015: 1-14. 36. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochem Biophys Res Commun. 2003; 300(2): 472-476. 37. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: Cross talk with the osteoblastogenic program. Cell Mol Life Sci. 2009; 66(2): 236-253. 38. Muruganandan S, Parlee SD, Rourke JL, Ernst MC, Goralski KB, Sinal CJ. Chemerin, a novel peroxisome proliferator-activated receptorγ (PPARγ) target gene that promotes mesenchymal stem cell adipogenesis. J Biol Chem. 2011; 286(27): 23982-23995.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
